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Tissue Organ Distribution and Behavioral
Effects of Platinum Following Acute and
Repeated Exposure of the Mouse to
Platinum Sulfate
by Bradley A. Lown,* John B. Morganti,*
Carl H. Stineman,t Rosemary B. D'Agostino, and
Edward J. Massarot
Platinum sulfate wasadministered intragastrically (IG) toadult maleSwiss micein asingledoseatthe 7
dayLD5orLD2s level. Controlgroupsreceived0.25M H2SO4(pH0.85)or0.14MNaCl.Openfieldbehavior
(anbulations, rearings) wasmeasured, andtissue/organ Ptlevelsdetermined at4hr, or 1,3, or7dayspost
administration. Atall times, the LD2s depressed ambulationsslgniflcantly and rearings marginally. Itdid
noteffect exploratory ("hole-in-board") behavior. The LD25 resulted indisproportionately high tissue Pt
levelsrelative totheLD5. There weresignificant inverse correlations betweenbehaviorand tissuePt levels
for most tissues, but not for brain.
Inrelated experiments, adult male mice weresubjected torepeated IG administration ofPt(SO4)2 at the
LDi level (onedoseevery 72 hrfor up to 10doses). Three daysafteradministration ofthefinaldoseofeach
series, open-field and exploratory performance were measured and tissue/organ Pt levels determined.
Tissue/organ Pt levels were variable but generally increased with dose number. No Pt was detected in the
brain. Activity and explorations were marginally depressed. Only rearings correlated significantly with
tissue Pt levels.
Introduction
Until relatively recently, human exposure to
platinum (Pt) and Pt compounds has been limited
mainly to the workplace (e.g., mining and refining
and the manufacture and reprocessing of catalysts)
and laboratory. However, accompanying the intro-
duction of the automobile catalytic converter (1975
automobile model year), the therapeutic use of Pt
complexes with antitumor activity (1), and the in-
evitable increase in coal utilization (which, overall,
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will release significant quantities of Pt), a potential
for widespread, long-term environmental dissemi-
nation and increased bioavailability of Pt exists.
Much ofourknowledge ofthe biological effects of
Pt has been derived from studies of Pt complexes
with anti-neoplastic activity, primarily cis-dichloro-
diamineplatinum(II) (1, 2). It has beenobserved that
followingparenteral administration, suchcomplexes
arerapidlyexcreted, primarily intheurine, mostly in
unchanged form. In man and experimental animals,
the half-time ofelimination ofthese complexes is of
the orderof 1-15 hrfor 80o ofthe dose, the remain-
ing 20%o being eliminated slowly over a period of
weeks. The complexes tend to accumulate in the
fitering organs (i.e., the kidney, liver, spleen, and
thymus) and in populations of dividing cells. Thus,
characteristic side effects of antitumor chemother-
apy with Pt complexes are observed. Of great im-
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convoluted tubules (resulting from the accumulation
ofhigh levels ofPtinthe kidney) whichterminates in
nephrosis. Destruction of the gastrointestinal
epithelium also occurs and, in humans, is dose-
limiting. In addition, high doses of cis-dichloro-
diamineplatinum(II) are ototoxic, depress bone mar-
row function, and induce nausea and emesis (3-8).
Much remains to be learned aboutthe interactions
ofother types ofPt compounds with biological sys-
tems. In animal studies, it has been observed that
orally administered PtC14 is poorly absorbed (less
than 0.5%) (9, 10). Of the absorbed Pt, between 50
and 70%o Pt is excreted via the urinary route; the
remainder via the fecal route (9-11). Via the in-
travenous route ofadministration, the highest levels
ofPt are found in the kidney, spleen, and liver, and
elimination half-times ofthe order of2.5 to 7.5 days
are observed (8-11). These retention/elimination
characteristics appear to be similar to those of cis-
dichlorodiamineplatinum(II) in humans (12).
Platinum compounds also have been shown to be
allergenic in the majority of exposed industrial em-
ployees (13). Symptoms include bronchial asthma,
allergic rhinitis, eczema, itching, and dermatitis (13,
14).
Except for cases of high sensitivity, it would ap-
pear that exposure to relatively high doses of Pt is
required to elicit overt toxicity. However, it is of
considerable importance to be cognizant of the fact
that long-term, low-level (classically subphar-
macological) exposure to environmentally available
toxicants may result, in an insidious manner, in
covert toxicity manifested, for example, by be-
havioral alteration(15, 16). Inthiscontext, nothingis
known about Pt compounds.
Thus, employing the mouse as a model mamma-
lian system, we undertook to investigate the effects
of acute and repeated (subacute) exposure to Pt
(sulfate) on: tissue/organ uptake of Pt, selected be-
haviors (open field, exploratory), and the relation-
ship between tissue/organ Pt levels and behavioral
effects.
Materials and Methods
Animals
Male random-bred Swiss mice (ICR strain, West
Seneca Laboratories, West Seneca, NY) 6-8 weeks
old, served as subjects in all studies. The animals
were acclimated to the laboratory for at least one
week prior to use. For all experiments except the
dose determination study, they were housed indi-
vidually in suspended metal mouse cages (Hoeltge,
Inc., Cincinnati, Ohio). For the dose determination
study, the animals were maintained in groups offive
perdouble cage. All were fed ad libitum on Charles
River RMH 1000 diet (Agway, Inc., Syracuse, NY),
and were maintained on a 12 hr light/dark cycle at
220C.
Reagents
All chemicals were of the highest grade available
commercially.
Acute (Single-Dose) Exposure to Pt(SO4)2
Dose Determination. A 7 day mortality-dose re-
sponse study was conducted forthe intragastric (IG)
route of administration. Lethal dose percentiles
(.D1... .LD,,) were calculated by probit analysis.
Tissue/Organ Uptake and Behavioral Effects.
Subjects in this study were 160 animals.
The7-day LD5 and LD25 were selectedforinvesti-
gation. At these concentrations, the pH of the
Pt(SO4)2 solutions was approximately 1.0. To com-
pensate for possible effects of simultaneous ex-
posure to low pH and sulfate, a low pH sulfate con-
trol (containing no Pt) was included inthe study. The
sulfate concentration and pH of this solution were
identical to those ofthe LD25 dose. To identify pos-
sible effects on behavioral performance ofexposure
tolowpHand sulfate, asalinecontrolgroupalso was
investigated. Thus, the animals (groups of 40, ran-
domly selected)received 144mgPt/kg(LD5); 213 mg
Pt/kg(LD25); 0.25M sulfuric acidadjusted topH 0.85
(pH of LD25 solution) with sodium hydroxide, or
0.14M sodium chloride. In each case, the volume
administered was equivalent to 1% (on a volume/
weight basis) of body weight. The animals were
lightly etherized prior to administration for ease and
consistency of dosing.
The animals were observed in an automated open
field (model 1497, Lehigh Valley Electronics,
Fogelsville, PA) at 4 hr or 1, 3 or 7 days post admin-
istration. Each subject was placed initially in the
centercircle (diameter = 15 cm)ofthe open field and
was observed for 5 minutes. The dependent mea-
sures, which we view as providing an index of gen-
eral activity, were total ambulations (automatically
recorded) and total rearings (visually recorded). A
rearing was scored each time the subject raised both
forepaws off the floor in the absence of grooming
behavior.
hnmediately after observation, the animals were
sacrificed by overdosing with ether and were dis-
sected. Blood was obtained by cardiac puncture and
the liver, spleen, kidneys, lungs, testes, skeletal
muscle, cerebrum, cerebellum and medulla were
removed, weighed and placed in acid washed test
tubes.
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the tissue Pt levels ofanimals not receiving Pt were
below the detection limit of the assay. Therefore,
only the tissues ofPt group animals were analyzed.
Tissues of the Pt group animals were analyzed by
flaneless atomic absorption spectroscopy employ-
ing a wet ashing procedure modified that described
by Tillery (17). Samples were collected in acid
washed test tubes. Concentrated nitric acid, 5 ml,
was added, and the samples were heated to 70°C to
initiate digestion of the tissues. The nitric acid was
boiled offand 5 ml concentrated HCl was added and
boiledoff; 2 mlof70%o perchloric acidwas added and
heated to approximately 200°C to complete diges-
tion. The perchloric acid was boiled off, and a Pt-Sn
complex was formed by the addition of a 2% stan-
nous chloride solution in 3M HCl. The negatively
charged complex was extracted with two 0.5 ml
aliquots of 20 mM tri-n-octylamine in xylene. Ex-
traction was necessary to obtain Pt free of interfer-
ring inorganic salts present in the tissues. Platinum
levels were measured on a Perkin-Elmer Model 360
atomicabsorption spectrophotometerequipped with
aModel HGA-2100graphite furnace. A 25IlI aliquot
of the sample in xylene solution was placed in the
graphite furnace. The sample was dried at 160°C,
charred at 900°C, and atomized at 2700°C. Samples
were compared to a standard curve included in each
run, obtained from aqueous standards extracted into
xylene in the same manner as the samples.
Analyses of variance (ANOVA) and overall as-
sociation and correlation analyses were performed
byusing the Multivariance Computer Program, ver-
sion 5.3 (18). Simple effects were investigated using
Tukey's Honestly Significant Difference Test per-
fonned by the Statistical Package for the Social Sci-
ences (SPSS) version 6.0, subprogram one way (19).
Lethal dose percentiles(LD..) andconfidence inter-
vals were obtained by probit analysis (18) using an
Isobol computer program (20).
Exploratory Behavior. Subjects were 160 male
mice. Dosing was performed as described above in
the Pt(S04)2 single-dose open field study.
Behavioral observation wascarried outby placing
thesubjects in a5.7 cm widecircularrunwayformed
from two concentric walls with an outside diameter
of34.3 cm. In the outside wall were four holes, 1.3
cmindiameter, centered900 apart and 5.1 cm above
thefloor. Photocells were so arranged thateach time
theanimal placed its snout into a hole the event was
counted. Thus, the measure ofexploratory behavior
was the number of hole entries (automatically re-
corded) in a5 minperiod. Therunwaywasespecially
designed to minimize general activity and maximize
exploratory activity.
Multiple Exposures to Subacute Doses of
Pt(SO4)2
Open Field and Exploratory Behavior Studies.
Subjects were 250 animals. Of these, 100 animals
(plus an allowance for probable deaths) were as-
signed (randomly) both to the Pt and low pH groups,
while 50 (plus an allowance) were assigned to the
saline control group.
The experimental animals received 1 to 10 doses
(IG) ofPt at the 7 day LD1 level of 109 mg Pt/kg in a
volume equivalent to 1% (v/w) ofbody weight. Low
pH controls received an equal volume of 0.15M
H2SO4 adjusted to pH 1.18 with NaOH (which was
identical in sulfate concentration and pH to the Pt
solution). Saline controls received an equivalent
volume of0.14M NaCl. Three days afteradministra-
tion, ten animals each from the Ptandlow pH groups
and five animals from the saline group were ran-
domly selected and observed for behavioral altera-
tions. The remaining animals were dosed again as
described andthisprocedure was repeated foratotal
of ten dosings.
The animals were observed in the automated open
field and the exploratory apparatus as in the single
dose studies described above. Halfofthe animals in
each treatmentgroup were observedfirst inthe open
field and then in theexploratory apparatus. With the
other half, the procedure was reversed.
Immediately following behavioral observation
after doses 2, 4, 6, 8, and 10, the Pt group animals
were sacrificed and a blood sample, the liver, kid-
neys, spleen, lung, gastrointestinal tract, testes, and
brain were collected in acid-washed test tubes. Tis-
sue Pt concentrations were determined as described
above.
Results
Exposure to a Single Dose ofPt(SO4)2 at the
LD5 or LD25 Level
Seven Day Mortality-Dose Response Studies
(DoseDetermination). The seven day IG LD5o for Pt
(S04)2 [pH range = 1.06 (150 mg Pt/kg body weight)
to 0.46 (500 mg Pt/kg)] was 280.5 mg Pt/kg (95%
confidence limits: 237.6 - 320.1 mg Pt/kg). No deaths
occurred in control groups.
Open Field Behavior and TissuelOrgan Distribu-
tion. The results of the open field study were
analyzedbyusing atwo-way (time ofobservationby
treatment) multivariate ANOVA (Table 1). The time
effect was significant overall and for ambulations,
separately. The time effect for rearings approached
significance. The treatment effect, which compares
all subjects receiving each treatment with those re-
February 1980 205Table 1. Analysis of variance ofopen field behavior.
Effects being tested
Time by
Variable Time Treatment treatment
Multivariate d.f. 6 and 286 6 and 286 18 and 286
F-Ratio 2.76 (p<0.01) 2.61 (p<0.02) 0.69 (N.S.)
Univariate d.f. 3 and 144 3 and 144 9 and 144
F-Ratios
Ambulations 3.68 (p<0.01) 4.85 (p<0.005)
Rearings 2.38 (p<0.07) 2.43 (p<0.07)
ceiving other treatments regardless of the time of
observation, also was significant overall and for am-
bulations, separately. Again, iearings approached
significance. The time by treatment effect, which
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FIGuRE 1. Effects OfPt(SO4)2 on mouse openfieldbehavior. Pt(SO4) wasadministered intragastrically to
6-8 weekold male random bred Swiss mice in avolumeequivalent to 1% (v/w) ofbodyweight. LD5 =
144 mg Pt/kg; LD2s = 213 mg Pt/kg; Low pH control = 0.25M H2SO4 adjusted to pH 8.5 (pH ofLD2s
solution) with NaOH; saline control = 0.14M NaCl.
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tests for interactions of the two main effects (time
and treatment) that are not simply additive, was not
statistically significant.
To determine the basis of the time and treatment
effects, thebehavioral data(Fig. 1)were subjected to
Tukey's Honestly Significant Difference Test (19).
The time effect for ambulations was found to be due
tothe4hranimalshavinglowerscoresthanthe 1-day
animals. However, neither of these groups differed
significantly from the 3-or 7-day groups. The treat-
ment effect for ambulations was due to the LD25
groups having lower scores than all other treatment
groups (which did notdiffer amongthemselves). For
rearings, the treatment effect only approached sig-
nificance. However, the pattern for rearings paral-
leled that for ambulations.
Tissue/organ Pt concentrations (for the Pt groups
4 Hours I Day 3 Days 7 Days
206Table 2. Analysis of variance of tissue/organ Pt concentrations in adult male mice
receiving a single dose of Pt(SO4)2 at the LD5 or LD25 level.
Effects being tested
Time
Variable (post administration) Dose Time by dose
Multivariate d.f. 30 and 182.66 10 and 62 30 and 182.66
F-ratio 8.80a 9.Iga 3.33a
Univariate d.f. 3 and 71 1 and 72 3 and 71
F-ratios
Blood 3.80b 20.87a 1.85
Liver 2.71c 32.91a 1.03
Spleen 1.12 43.29a 0.79
Kidney 7.05a 13.24a 2.58
Lung 7.69a 20.31a 2.56
Testes 6.Ola 77.75a 2.18
Muscle 8.04a 28.73a 5.09b
Cerebrum 12.71a 1.06 0.60
Cerebellum 45.61a 1.9 5.75b
Brain stem 12.03a 1.48 0.31
ap < 0.001.
bp < 0.01.
cp < 0.05.
only) were subjected to a multivariate ANOVA cerebellum had significant univariate effects.
(Table 2). There was a significant multivariate time The effects of time and dose on tissue/organ Pt
effect with significant univariate effects for all tis- concentrations are shown in Table 3. It is apparent
suesexcept spleen. The multivariate dose effect also that there is a time differential in the attainment of
was significant with significant univariate effects for maximum Pt levels among different tissues/organs.
all tissues except brain. The multivariate time by Thus, Pt concentrations in the blood, kidney, lung,
doseinteraction was significant; butonlymuscle and muscle, and brain tissue are highest at 4 hr post
Table 3. Tissue/organ Pt concentrations tissue at various times post administration in adult male mice
receiving a single dose of Pt(SO4)2 at the LD5 or LD25 level.
Pt concn, iLg Pt/g wet weighta
Pt dose,
mg/kg Tissue 4 hr 1 day 3 days 7 days
144 Blood 5.9 ± 4.3 3.4 ± 4.2 2.1 ± 0.9 1.2 ± 1.0
(LD5) Liver 8.1 ± 5.1 8.6 ± 12.1 4.9 ± 2.6 1.0 ± 1.3
Spleen 2.2 ± 1.3 2.7 ± 3.2 2.4 ± 1.1 1.3 ± 0.5
Kidney 12.8 + 6.2 7.5 ± 7.2 6.3 ± 7.4 1.3 ± 1.3
Lung 7.4 ± 8.3 2.6 ± 2.8 1.8 ± 0.5 1.4 ± 2.0
Testes 1.3 ± 1.2 0.7 ± 0.7 0.5 ± 0.2 1.3 ± 1.0
Muscle 0.6 ± 0.6 0.3 ± 0.3 0.2 ± 0.1 0.1 ± 0.1
Cerebrum 0.9 ± 1.2 0.1 ± 0.2 0.0 ± 0.0 0.2 ± 0.1
Cerebellum 0.9 ± 0.5 0.3 ± 0.3 0.0 ± 0.1 0.2 ± 0.2
Medulla 0.6 ± 0.8 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
213 Blood 29.8 ± 31.6 15.9 ± 14.0 14.4 ± 12.8 6.5 ± 3.5
(LD25) Liver 28.5 ± 22.7 34.6 ± 33.0 37.6 ± 26.6 13.9 ± 7.9
Spleen 12.7 ± 11.3 12.8 ± 11.2 18.7 ± 13.9 10.8 ± 5.9
Kidney 48.5 ± 51.7 25.0 ± 17.7 20.2 ± 12.5 1.5 ± 0.7
Lung 27.2 ± 18.5 16.4 ± 20.2 8.9 ± 6.8 3.8 ± 1.8
Testes 4.3 ± 2.6 2.8 ± 2.1 3.1 ± 1.2 5.8 ± 2.2
Muscle 3.7 ± 2.5 2.1 ± 2.4 1.0 ± 0.7 0.4 ± 0.2
Cerebrum 1.4 ± 1.4 0.2 ± 0.4 0.1 ± 0.2 0.2 ± 0.1
Cerebellum 1.6 ± 0.8 0.0 ± 0.0 0.1 ± 0.2 0.3 ± 0.2
Medulla 0.8 ± 0.7 0.2 ± 0.4 0.0 ± 0.1 0.2 ± 0.1
aMeans ± SD.
February 1980 207Table 4. Correlations between open field behavioral measures and
tissue/organ Pt concentrations in animals receiving a single dose of
Pt(SO4)2 at the LDs or LD2s level.
Tests of the Overall
hypothesis of F =2.45, p<0.001 d.f. = 20 and 134
no association
between behavior Ambulations Rearings
and tissue Pt F = 3.98, F = 3.35,
concentrations p < 0.001 p < 0.001
d.f. = 10/68 d.f. = 10/68
Correlation coefficients d.f. = 78
Blood -0.487a -0.394a
Liver -0.452a -0.346a
Spleen -0.553a -0.469a
Kidney -0.384a -0.271b
Lung -0.413a -0.345a
Testes -0.476a -0.390a
Muscle -0.323a -0.216
Cerebrum -0.159 -0.097
Cerebellum -0.211 -0.125
Brain stem -0.195 -0.163
ap <0.01.
bp <0.05.
administration forboth doses. Liverand spleen con-
centrations at the LD25 level rise to a maximum at 3
days and decrease by 7 days. For the LD5 levelthey
peak at 1day and then decrease. In the testes, the Pt
concentration is high (relatively) initially, decreases
one and three days post administration, and returns
tothe initial level orhigher at sevendays. Regarding
dose, it is of interest to note that tissue/organ Pt
concentrations in the LD25 groups were three to ten
times higher than in the LD5 groups eventhough the
high dose groups received only about 1.5 times as
much Pt.
Relationship between Open Field Behavior and
Tissue Pt Levels. The correlations between be-
haviorand tissue/organ Pt concentrations are shown
in Table 4. Again, the data for this analysis were
derived from the Pt-treated animals only, since Pt
concentrations were undetectable in control ani-
mals. Theperformance scores forindividual animals
for each behavioral task and the Pt levels of the
tissues of each animal formed the basis of the
Table 5. Effects of exposure'to multiple (repetitive) doses of Pt(SO4)2 at the LD1 level on
open field (ambulations and rearings) and exploratory behaviors of the mouse.
Platinum Low pH Saline
Behavior Doses (mean + SD) (mean ± SD) (mean ± SD)
Ambulations 1 172.0 ± 42.8 174.4 + 18.6 160.0 ± 27.3
2 193.6 ± 49.6 190.8 ± 28.7 174.6 ± 29.8
3 181.2 ± 34.6 195.3 ± 49.9 208.2 ± 46.1
4 190.0 ± 43.6 190.2 ± 35.3 175.6 ± 38.7
5 171.5 ± 34.7 180.6 ± 44.9 184.0 ± 78.2
6 1%.1 32.7 189.3 + 5.% 207.2 + 76.8
7 134.9 + 57.0 196.6 ± 58.7 186.2 ± 49.5
8 165.9 ± 24.9 175.3 ± 39.7 187.2 + 34.6
9 141.4 ± 47.2 176.6 ± 34.1 184.0 ± 43.2
10 176.7 ± 30.2 199.2 ± 53.3 200.8 + 36.4
Rearings 1 40.1 ± 16.6 38.2 ± 19.9 29.4 ± 7.9
2 42.3 + 9.4 51.5 ± 15.2 36.8 ± 16.6
3 40.7 ± 11.6 37.1 ± 8.9 35.8 ± 6.8
4 42.9 ± 13.6 35.6 ± 12.7 31.6 ± 14.8
5 37.8 ± 9.1 33.8 + 8.0 39.2 ± 19.9
6 33.6 + 13.1 35.6 ± 18.1 31.6 + 13.7
7 25.2 ± 15.6 33.2 ± 12.6 45.0 ± 11.4
8 25.6 ± 8.9 23.4 ± 10.0 34.2 ± 14.8
9 21.6 ± 8.3 30.3 ± 9.3 27.8 ± 13.7
10 23.3 ± 6.8 33.7 _ 13.9 39.6 ± 7.4
Explorations 1 29.4 ± 10.9 30.9 ± 10.8 36.6 ± 15.5
2 28.7 ± 17.6 40.6 ± 12.2 42.2 ± 15.4
3 37.6 ± 16.7 29.5 ± 18.7 33.4 ± 14.4
4 38.2 ± 19.5 28.1 ± 14.1 20.0 ± 7.9
5 27.2 ± 15.6 31.8 ± 20.2 36.2 ± 19.2
6 27.1 ± 14.6 41.0 ± 13.3 43.4 ± 26.8
7 28.8 ± 20.1 38.2 ± 10.5 40.0 ± 16.9
8 35.5 ± 20.9 35.6 ± 13.1 34.6 ± 12.0
9 30.1 ± 22.8 33.6 ± 17.1 34.8 ± 16.4
10 17.9 ± 15.6 42.4 ± 14.1 47.4 ± 11.9
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Effects being tested
Variable Number of doses Treatment Doses x treatment
Multivariate d.f. 27/637.31 6/436 54/650.37
F-ratio 2.37 (p<0.001) 1.97 (N.S., p<0.07) 1.27 (N.S., p<0.10)
Univariate d.f. 9/220 2/220 18/220
F-ratiosb
Ambulations 1.61 (N.S.) 3.29 (p<0.05) 0.83 (N.S.)
Rearings 5.04 (p<0.001) 0.66 (N.S.) 1.69 (p<0.05)
Explorations 0.42 (N.S.) 3.86 (p<0.05) 1.49 (N.S., p<O.1O)
aThe data were analyzed by a two-way analysis ofvariance. The factors were: number ofdoses and treatment (platinum sulfate, low
pH, saline).
bUnivariate F-ratios normally are not examined if the corresponding multivariate F-ratio was not significant at the p<0.05 level.
However, in these studies, while formally retaining the critical level ofp<0.05, we are noting significance levels up top<O. 10.
analysis. The correlations were determined via mul-
tivariate tests of no association which indicate, in
thiscase, whetherthetwo setsofvariables, behavior
and tissue/organ Pt concentrations, were associated
with one another. These tests revealed significant
associations forbothopen field behavioral measures
(ambulations, rearings) together and, also sepa-
rately.
Ambulations were significantly correlated with all
tissue Pt concentrations except those of brain.
Likewise, rearings were correlated with all tissue
concentrations except those of brain and skeletal
muscle. Both ambulations and rearings had strong
negativecorrelations with spleen, blood,testes, liver
and lung (in decreasing order) and aweaker correla-
tion with kidney. The negative correlations indicate
that the more depressed behavioral scores were as-
sociated with the higher tissue/organ Pt concen-
trations.
Exploratory Behavior Study. These behavioral
data were analyzed by using a two-way (time of
observation by treatment) univariate ANOVA.
Significant effects oftime (F = 6.66, d.f. = 3/144,
p < 0.001) and time by treatment (F = 1.92, d.f. =
9/144,p < 0.05) were found. Tukey's Honestly Sig-
nificant Difference Test of the time effect showed
exploratory behavior higher at 4 hr than all other
times with no difference among the other times.
The time by treatment interaction primarily ap-
pears to be due to the 4 hr low pH control group
which explored significantly more than the 4 hr Pt
treated or saline control groups. In fact, all groups
were similar at4 hrwith the exception ofthe low pH
group. The balance ofthe interaction is taken up by
thefact that exploratory behavior decreased at 1, 3,
and 7 days for all groups except the saline control
group whose behavior remained constant across
time.
Exposure to Multiple (Repetitive) Doses of
Pt(SO4)2 at the LD1 Level
Open Field and Exploratory Behavior. The
means (+ SD) for the three behavioral measures
(ambulations, rearings and explorations) are pre-
sented in Table 5. Multivariate ANOVA of these
data (Table 6) revealed a significant effect of dose
number with rearings as the only significant uni-
variate measure. The treatment effect approached
significance (p < 0.07) with significant univariate
F-ratiosforambulations andexplorations. Thedoses
by treatment interaction also approached signifi-
cance with a significant univariate effectforrearings
and with explorations approaching significance.
Tukey's Hones,tly Significant Difference procedure
revealed that rearings were depressed following
doses 7, 8, 9, and 10 compared to dose 2 and were
also depressed following doses 7 and 8 compared to
dose3. Tukey'sprocedure is notentirelyefficientfor
unequal cell frequencies and failed to find any pair-
wise differences among treatments for ambulations
andexplorations despite significant overallF-ratios.
Therefore, linearcombinations ofthe treatments (Pt
vs. low pH and saline, and low pH-vs. saline) were
tested ast-statisticstolocatetheeffect. Ambulations
and explorations were found to be depressed in the
Ptgroups relative to the control groups by this pro-
cedure while the control groups did not differ. The
time by treatment interaction for rearings arose be-
cause, at times 7 and 10, scores for the Pt groups
were lower than those for the saline controls. The
time by treatment interaction for explorations arose
because at time 10 only, the Pt group scores were
lower than those of both control groups.
Tissue/Organ Pt Levels Following Exposure to
Multiple (Repetitive) Doses ofPt(S04)2 at the LDl
Level. Tissue/organ Pt levels were analyzed by
February 1980 209Table 7. Tissue/organ Pt concentrations in adult male mice receiving multiple (repetitive) doses Pt(SO4)2 at the LDi level.
Tissue/organ Pt concns, ,ug/g (wet weight)a
Number of
doses Blood Liver Kidney Spleen Lung GI tract Testes
2 0.19 ± 0.11 0.15 ± 0.13 1.88 ± 2.12 0.23 ± 0.29 1.23 ± 3.27 0.13 ± 0.09 0.10 ± 0.12
4 0.50 ± 0.32 0.35 ± 0.26 2.71 ± 1.67 0.72 ± 0.43 1.40 ± 2.65 0.16 ± 0.12 0.28 ± 0.17
6 1.18 ± 0.63 0.58 ± 0.32 3.90 ± 1.78 1.95 ± 1.69 3.30 ± 7.78 1.04 ± 1.78 0.53 ± 0.34
8 1.07 + 1.05 1.22 ± 1.33 6.84 ± 4.86 2.61 ± 3.69 4.51 ± 5.56 0.29 ± 0.27 0.60 ± 0.35
10 1.03 + 0.77 0.% ± 0.53 8.29 ± 8.48 2.11 ± 1.70 8.30 ± 8.91 0.45 ± 0.50 0.57 ± 0.36
aMeans ± SD.
using a one-way (dose) multivariate ANOVA. cantly associated with tissue Pt levels was rearings.
The tissue Pt concentrations are presented in Significant inverse correlations were found between
Table 7. Brain levels were uniformly undetectable rearings and liver, testes, kidney, spleen, and blood
(less than 0.15 ug Pt/g tissue) and, therefore, were Pt levels.
not recorded. Multivariate ANOVA revealed a sig-
nificant effect of dose number (F = 2.14, d.f. = Discussion
28/142,p < 0.01). Thedoseeffectalsowassignificant
forblood (F = 4.09, d.f. = 4/45,p < 0.01), liver(F = In 1975 Moore etal. (10) reported onthebiological
4.29, d.f. = 7/45,p < 0.01), kidney (F = 3.55, d.f. = fate of single doses of '91PtC14 in the rat. They ob-
4/45,p < 0.05) and testes (F = 5.80, d.f. = 4/45,p < servedthatmostoftheperorallyadministeredPtwas
0.001), and very nearly significant for spleen (F = not absorbed; being eliminated in the feces. In the
2.56, d.f. = 4145,p < 0.0511). In all cases, the effect studies we report, exposure to a single IG dose of
was one of higher Pt concentrations at higher num- Pt(SO4)2 at the LD5 or LD25 levels resulted in sys-
bers of doses. temic distribution of a quantity of Pt representing
Relationship between BehavioralMeasures (Open onlyasmallfractionofthe administered dose. Thus,
Field and Exploratory) and Tissue/Organ Pt although we did not analyze feces, and cannot,
Levels. The results of the overall tests of associa- therefore, confirm their findings directly, our find-
tion and the correlations between behavioral mea- ings are consistent with those of Moore et al. (10).
sures and tissue Pt levels (for the Pt-treated groups Tissue Pt levels following exposure to a single
observed after2, 4, 6, 8, and 10 doses) are presented LD2s dose of Pt(SO4)2 are disproportionately high
in Table 8. relative to the tissue levels following exposure to a
A significaiit overall association was found. How- singledose atthe LD5 level. We have noexplanation
ever, the only individual behavioral measure signifi- forthis observation. However, it is conceivable that
Table 8. Relationship between open field and exploratory behavioral measures and tissue Pt levels:
Pt(S04)2 multiple (repetitive) exposure study.a
Tests of no - Overall F = 1.683, d.f. = 21/115.4085, p<0.05
association
between Ambulations Rearings Explorations
behavioral and F= 1.24, df=7/42, F=2.80, df=7/42, F=1.47, df=7/42,
tissue measures N.S. p < 0.02 N.S.
Correlation coefficients
(d.f. = 49)
Blood -0.132 -0.285b -0.088
Liver -0.210 -0.425c -0.112
Kidney -0.259 -0.371c -0.237
Spleen -0.194 -0.301b -0.035
Lung -0.231 -0.232 -0.357c
GI 0.010 -0.025 -0.044
Testes -0.228 -0.378c -0.047
aTissue Pt levels were determined only in the Pt dosed animal groups. In all other groups, tissue/organ levels were below the limit of
detectability.
bp < 0.05.
Cp < 0.01.
Environmental Health Perspectives 210thehigher Pt dose may damage or stress the GI tract
in some manner, resulting in increased Pt absorp-
tion. Alternatively, or in addition, the higher Pt con-
centrations found in the blood and kidneys of
animals dosed at the higher level may damage the
kidneys [whichnormally appeartoeliminate Ptquite
efficiently (21, 22)], resulting in decreased Pt excre-
tion. Furthermore, itiswell knownthatsomemetals,
such as cadmium and lead, bind to proteins and in
some cases (e.g., Cd) induce the synthesis of their
ownbindingproteins (23, 24). Platinummayfunction
similarly.
Acute exposure to Pt(SO4)2 significantly de-
pressed ambulations in the openfield and marginally
depressed rearings (but only atthe LD25 dose level).
For ambulations, this pattern persisted from 4 hr
through 7 days after administration, although the
effectwas most pronounced at 4 hr(Fig. 1). A corre-
lation analysis (Table 4) revealed highly significant
negative correlations between open field behaviors
and tissue levels of Pt for all tissues except brain
(and, in the case ofrearings, skeletal muscle). Since
brain Pt levels do not appear to be related to be-
havior, it is not clear how tissue Pt levels affect
behavior. Waters et al. (25), working with alveolar
macrophagesintissueculture, reported a50%lossof
viability (ability toexclude Trypan Blue)aftera20hr
exposure to 300mM PtC14. Protein and RNA syn-
thesis were inhibited by 50% by 60mM Pt and DNA
synthesis was inhibited by 50% by lOmM Pt. The
maximum tissue Pt concentration observed in our
studywas approximately 50ppmfound inthe kidney
4 hr post administration of a single LD25 dose of
Pt(SO4)2. A level of50 ppm is approximately equiv-
alent to 250mM Pt. Therefore, by analogy to the
findings ofWaters et al. (25), cellularprocesses may
have been disrupted to some extent in the LD25-
dosed animals which could have produced general
malaise and depressed behavior.
Exposure to a single dose ofPt(SO4)2, even at the
LD25 level, did not appear to alter "hole-in-board"
exploratorybehaviorofthe mouse. Whilethere were
significant effects of time and a time by treatment
interaction, scrutiny of these effects indicates that
theywere notrelated to Ptexposure perse. The high
rate ofexplorations ofthe 4 hrlow pH control group
(see Results), for which no satisfactory explanation
is presently available, probably sufficiently accen-
tuated the difference between the 4 hr time and all
othertimes to account for the significant main effect
oftime as well as the significant time by treatment
interaction.
Chronicexposure toPtwas simulatedbythe use of
alimited multiple dose experimental design (1 to 10
doses). Each dose equaled the 7 day LDi, which is
approximately 40%o of the 7 day LD5o. Thus, total
exposure, following 10 doses, was substantially
greater than the 7 day LD5o. In this study, tissue Pt
levels: were found to be low across doses, were
highly variable among tissues, and generally in-
creased with dose number, except for the brain in
which no Pt was detected (Table 7). The absence of
Pt in the brain is not surprising since the highly
charged Pt cation should be excluded by the blood-
brain barrier.
Analysis of variance of the open field and ex-
ploratory behavioral measures obtained inthe multi-
ple dose study indicated a significant multivariate
effect ofdose. The multivariate effects oftreatment
and the doses by treatment interaction approached
significance, and anumber ofthe univariateF-ratios
were significant (Table 6). Relative to dose, there
was a highly significant difference in rearings be-
tween control and experimental animals. Also,
rearings showed significant negative correlations
withtissue Ptlevels (Table 8). Inlightofthe very low
tissue/organ Pt levels (Table 7), these observations
would appear to be highly significant.
A comparison of the single and multiple dose
studies indicates a consistent relationship between
the tissue/organ Pt levels and behavior (particularly
rearings). In the single dose study, relatively high
tissue Ptlevels were associated with strongly signifi-
cant behavioral effects while in the multiple dose
study, relatively lowtissue Pt levels were associated
withweak behavioral effects. In both cases, the cor-
relations between tissue Pt levels and rearings were
generally significant, with the notable exception of
the brain. Since these correlations involved a num-
ber oftissues, but not the brain, a general systemic
effect, rather than a neurotoxic effect, seems to be
indicated. Pt compounds have been shown to inhibit
DNA, RNA, andprotein synthesisin vitro (25)andin
vivo (1, 21). Our findings suggest that Pt has a de-
pressingeffectoncellular processes andexposure to
Ptabove a threshold level results in general malaise
which is manifested as a depression of certain be-
haviors. As Pt levels increase, the interference with
cellularprocesses and, therefore, behavioral depres-
sion is likewise increased.
In summary, Pt(SO4)2 administered via the IG
route appears to be poorly absorbed. However, with
the exception of brain tissue, the absorbed Pt
achieves general systematic distribution. With re-
peated exposure, tissue concentrations tend to in-
crease with dose; again, with the exception ofbrain
which did not accumulate Pt. While Pt did affect
behavior under conditions of single and multiple
doseexposure, theseeffects wereweakexceptwhen
veryhigh (LD25)individual doseswere employed. In
the latter case, the behavioral effects were more
pronounced and lasted for up to 7 days post admin-
February 1980 211istration (end ofobservation). Theconsistent pattern
of relationship between tissue levels of Pt and be-
havioris suggestive ofinterference withcellularpro-
cesses induced by Pt at concentrations greater than
some threshold value. This interference is man-
ifested as behavioral malaise.
It is difficult to predict the potential danger of
increased anthropogenic redistribution of Pt in the
environment. Toxicity has been observed in humans
exposed to high Pt levels in the workplace or dur-
ing antitumor chemotherapy. However, such dose
levels are many times those that would ever be
expected to occur in the general environment.
Nevertheless, since exposure to Pt appears to alter
certain behaviorofthe mouse, tOe possibility ofsub-
tle adverse biological and behavioral effects result-
ing from long-term low levei (environmental) ex-
posure of humans cannot be disregarded especially
inthelightofthefactthatPtcanbemethylated(26)in
a manner analagous to that of mercury (27). By al-
tering its physicochemical properties, methylation
may, as in the case of mercury (28) greatly enhance
the toxicity of Pt and its bioaccumulatability.
This research was supported by the United States Environ-
mental Protection Agency through contract No. 68-02-1768.
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